Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Open Access
- 26 June 2007
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (2) , 145-151
- https://doi.org/10.1038/sj.bjc.6603860
Abstract
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.Keywords
This publication has 35 references indexed in Scilit:
- In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patientsBritish Journal of Cancer, 2006
- Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1Pharmacogenetics and Genomics, 2006
- Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and SurvivalClinical Cancer Research, 2006
- cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancerLung Cancer, 2005
- RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine ChemoresistanceClinical Cancer Research, 2005
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus CisplatinClinical Cancer Research, 2005
- The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas AdenocarcinomaClinical Cancer Research, 2004
- Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathwayThe Pharmacogenomics Journal, 2004
- Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional SurgeryClinical Cancer Research, 2004
- Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1Pharmacogenetics, 2003